SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a medical stage biopharmaceutical firm targeted on growing novel therapeutics to deal with unmet medical wants in viral and liver illnesses, has filed a response to the grievance of, and counterclaims in opposition to, Janssen Biopharma in California State Superior Court for the County of San Mateo.
The response to Janssen’s grievance particularly identifies the many years previous publicly obtainable info (printed patents and scientific literature), earlier work expertise, publications and patents by the Aligos co-founders at different oligonucleotide firms in the direction of the primary discovery of oligonucleotides (ASO and siRNA) concentrating on hepatitis B virus (HBV), in addition to the licenses Aligos obtained from universities and biotechnology firms – all of which had been utilized as the premise of Aligos’ HBV portfolio. The response additional outlines and paperwork that every one work was carried out by Aligos staff after leaving Janssen Biopharma.
The counterclaims in opposition to Janssen allege that Janssen has engaged in unfair competitors and promissory fraud. Aligos’ co-founders, Lawrence M. Blatt, Ph.D., MBA, and Leonid Beigelman, Ph.D., joined Aligos in submitting the counterclaims. The response and counterclaims will be discovered at their respective hyperlinks.
“I encourage everyone interested in this matter to read our response and counterclaims,” mentioned Lawrence M. Blatt, Ph.D., MBA, CEO, Chairman and co-founder of Aligos. “The facts are on Aligos’ side, and we will continue to defend ourselves from the baseless allegations made by Janssen.”
Aligos Therapeutics, Inc. is a medical stage biopharmaceutical firm that was based in 2018 with the mission to turn out to be a world chief within the therapy of viral infections and liver illnesses. Aligos is targeted on the invention and growth of focused antiviral therapies for persistent hepatitis B (CHB) and coronaviruses in addition to leveraging its experience in liver illnesses to create focused therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ technique is to harness the deep experience and many years of drug growth expertise its crew has in liver illness, significantly viral hepatitis, to quickly advance its pipeline of doubtless best-in-class molecules.
This press launch accommodates forward-looking statements inside the which means of the U.S. Private Securities Litigation Reform Act of 1995. Any statements on this press launch that aren’t historic details could also be thought-about “forward-looking statements,” together with with out limitation statements relating to Aligos’ persevering with to defend itself from the allegation made by Janssen. Forward-looking statements are sometimes, however not all the time, recognized by way of phrases similar to “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and different related terminology indicating future outcomes. Such ahead wanting statements are topic to substantial dangers and uncertainties that might trigger our growth applications, future outcomes, efficiency, or achievements to differ materially from these anticipated within the forward-looking statements. Such dangers and uncertainties embody with out limitation dangers and uncertainties inherent within the drug growth course of, together with Aligos’s clinical-stage of growth, the method of designing and conducting medical trials, the regulatory approval processes, the timing of regulatory filings, the challenges related to manufacturing drug merchandise, Aligos’s means to efficiently set up, defend and defend its mental property, different issues that might have an effect on the sufficiency of Aligos’s capital assets to fund operations, reliance on third events for manufacturing and growth efforts, modifications within the aggressive panorama and the results on our business of the worldwide COVID-19 pandemic and the growing battle between Russia and Ukraine. For an additional description of the dangers and uncertainties that might trigger precise outcomes to differ from these anticipated in these forward-looking statements, in addition to dangers relating to the business of Aligos on the whole, see Aligos’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 4, 2022 and its future periodic experiences to be filed or submitted with the Securities and Exchange Commission. Except as required by regulation, Aligos undertakes no obligation to replace any forward-looking statements to replicate new info, occasions or circumstances, or to replicate the prevalence of unanticipated occasions.
Amy Jobe, Ph.D.
+1 315 879 8192
Corey Davis, Ph.D.
+1 212 915 2577